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Scotland 
Approx. 8,200 
men to be 
surveyed 
England 
Approx. 82,000 
men to be 
surveyed 
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Approx. 5,600 
men to be 
surveyed 
N. Ireland 
Approx. 2,700 
men to be 
surveyed 
Figure 2: Survey numbers 
Background 
• Prostate cancer is the commonest cancer in men in the United 
Kingdom (UK) and the number of men with this disease is increasing.  
• Its treatment may impact physically, psychologically and socially, 
affecting the health-related quality of life (HRQL) of men and their 
partners/spouses.  
• In addition to improving treatments it is important to measure 
outcomes of importance to patients and partners/spouses so that 
services can be tailored to meet men’s needs.  
 
Study aims 
Through a series of interlinking work-streams (Figure 1) we will:  
• describe the HRQL of men with prostate cancer using qualitative and 
quantitative methods;  
• explore if and how their HRQL is associated with or predicted by 
disease, treatment and/or patient characteristics with a view to inform 
healthcare policy and service delivery; 
• describe levels of patient empowerment and explore the interaction 
between patient empowerment and HRQL; 
• undertake a study of men without prostate cancer to determine levels 
of symptoms in the community for comparison; 
• inform development of health care policy and service delivery. 
Figure 1: Study overview 
Figure 3: Survey timelines 
• We will identify prostate cancer survivors in all four UK countries 
through cancer registration or hospital administration systems.  
Eligible men will be between 15-39 months post-diagnosis (~100,000; 
Figure 2).   
• The first cohorts within each country will be surveyed twice, 12 
months apart, with second de novo cohorts surveyed once (Figure 3).  
• We have developed a comprehensive survey using generic and 
cancer-specific measures of HRQL, including EQ-5D, EPIC-26 and 
the Social Difficulties Inventory, plus patient perspectives measures 
(the Decision Regret Scale and Patient Empowerment Scale).  
• The survey will also include a free text box at the end of each section 
to capture any other important relevant issues not covered. 
• The survey data will be linked with administrative health data (e.g. 
Hospital Episodes Statistics, Radiotherapy Data Set) in order to 
maximise the amount of clinical and treatment information available. 
• We will also conduct telephone interviews with a sample of men who 
complete the survey (~100) along with a small number of 
partners/spouses (~20). 
 
 
Methodology 
Dissemination of results 
We will use traditional (reports and academic papers) and innovative 
methods (such as an electronic reporting tool) to ensure that results are 
widely available to men and their families, the funders, the NHS, social 
care, voluntary sector organisations and the research community.  
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